NervGen Pharma Corp. (NGEN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, NervGen Pharma Corp. (NGEN) has a cash flow conversion efficiency ratio of -2.913x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-10.13 Million) by net assets ($3.48 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
NervGen Pharma Corp. - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how NervGen Pharma Corp.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Read NervGen Pharma Corp. (NGEN) financial obligations for a breakdown of total debt and financial obligations.
NervGen Pharma Corp. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of NervGen Pharma Corp. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Range Capital Acquisition Corp. Ordinary Shares
NASDAQ:RANG
|
-0.001x |
|
Duxton Water Ltd
AU:D2O
|
-0.042x |
|
Kafrit
TA:KAFR
|
0.104x |
|
Shieh Yih Machinery Industry Co Ltd
TWO:4533
|
-0.001x |
|
Acusensus Ltd
AU:ACE
|
0.023x |
|
Intai Technology
TWO:4163
|
0.039x |
|
Aurum Resources Ltd
AU:AUE
|
-0.004x |
|
Beta Systems Software AG
F:SPT6
|
N/A |
Annual Cash Flow Conversion Efficiency for NervGen Pharma Corp. (2018–2025)
The table below shows the annual cash flow conversion efficiency of NervGen Pharma Corp. from 2018 to 2025. For the full company profile with market capitalisation and key ratios, see NervGen Pharma Corp. market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $3.48 Million | $-19.50 Million | -5.608x | +14.20% |
| 2024-12-31 | $1.79 Million | $-11.70 Million | -6.536x | -216.26% |
| 2023-12-31 | $-1.52 Million | $-8.52 Million | 5.622x | +525.55% |
| 2022-12-31 | $9.93 Million | $-13.12 Million | -1.321x | -168.70% |
| 2021-12-31 | $13.30 Million | $-6.54 Million | -0.492x | +53.85% |
| 2020-12-31 | $4.65 Million | $-4.95 Million | -1.065x | +23.12% |
| 2019-12-31 | $4.50 Million | $-6.24 Million | -1.386x | -234.95% |
| 2018-12-31 | $1.84 Million | $-761.52K | -0.414x | -- |
About NervGen Pharma Corp.
NervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company's lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), stroke, multiple sclerosis, and Alzheimer's… Read more